Review of extended-release formulations of Tramadol for the management of chronic non-cancer pain: Focus on marketed formulations

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 149-161

  Kizilbash, Arshi ^a   Ngô Minh, Cúong ^b  

^a Delta Health Services Inc   (Canada)

^b Somerset West Community Health Centre   (Canada)

Author keywords

Analgesics; Chronic pain; Drug delivery; Opioids; Pharmacokinetics; Tramadol

Indexed keywords

CODEINE; CONZIP; DURELA; FENTANYL; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RALIVIA; TRAMADOL; TRIDURAL; UNCLASSIFIED DRUG; ZYTRAM;

ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CANADA; CHRONIC PAIN; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH SERVICE; HUMAN; INCIDENCE; LIFESTYLE; MAXIMUM PLASMA CONCENTRATION; PREVALENCE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 84897139782     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S49502     Document Type: Review

References (54)

1. Pain: Hope Through Research [webpage on the Internet]. Bethesda: National Institute of Neurological Disorders and Stroke; 2009. Available from: http://www.ninds.nih.gov/disorders/chronic_pain/detail_chronic_pain.htm#215763084. Accessed September 17, 2013.
2. Assessment and Management of Chronic Pain [webpage on the Internet]. Bloomington: Institute for Clinical Systems Improvement (ICSI); 2011. Available from: http://www.guideline.gov/content.aspx?id=36064&search=chronic+pain. Accessed September 17, 2013.
3. Trescot AM, Helm S, Hansen H, etal. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11(2):S5-S62.
4. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589-1594.
5. Dominick CH, Blyth FM, Nicholas MK. Unpacking the burden: understanding the relationships between chronic pain and comorbidity in the general population. Pain. 2012;153(2):293-304.
6. Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770.
7. Canadian Pain Society [webpage on the Internet]. Pain in Canada Fact Sheet 2011. Available from: www.canadianpaincoalition.ca/media/canadian_pain_fact_sheet_22_10_10_en.pdf. Accessed September 17, 2013.
8. Tsang A, Von Korff M, Lee S, etal. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883-891.
9. Reitsma ML, Tranmer JE, Buchanan DM, Vandenkerkhof EG. The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 2008. Chronic Dis Inj Can. 2011;31(4):157-164.
10. Lynch ME, Watson CP. The pharmacotherapy of chronic pain: a review. Pain Res Manag. 2006;11(1):11-38.
11. Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am. 2007;33(1):1-31.
12. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: have we improved our management of chronic noncancer pain? Pain Res Manag. 2007;12(1):39-47.
13. Committee on Advancing Pain Research, Care, and Education; Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington: The National Academies Press; 2011.
14. International Association for the Study of Pain (IASP), European Federation of IASP Chapters (EFIC). Unrelieved Pain is a Major Global Healthcare Problem. Washington: International Association for the Study of Pain; 2013. Available Available from: www.iasp-pain.org/AM/Template.cfm?Section=Press_Release&Template=/CM/ContentDisplay.cfm&ContentID=2902. Accessed September 17, 2013.
15. World Health Organization. WHO's Pain Ladder for Adults. Geneva: World Health Organization; 2014. Available from: http://www.who.int/cancer/palliative/painladder/en/. Accessed September 17, 2013.
16. Marcus DA. Treatment of Nonmalignant Chronic Pain. Am Fam Physician. 2000;61(5):1331-1338.
17. Antman EM, Bennett JS, Daugherty A, etal. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
18. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2008;33(16):1766-1774.
19. Tannenbaum H et al. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol. 2006; Jan; 33(1):140-57. Epub 2005 Dec.
20. Bhatt DL, Scheiman J, Abraham NS, etal; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118(18):1894-1909.
21. Karhu D, Fradette C, Potgieter MA, Ferreira MM, Terblanché J. Comparative pharmacokinetics of a once-daily Tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration. J Clin Pharmacol. 2010;50(5):544-553.
22. Flick K, Frankus E. 1-(m-Substituted Phenyl)-2-Aminomethyl Cyclohexanols. 8 (1972). Available from: www.google.com/patents/US3652589. Accessed September 13, 2013.
23. Pregolizzi JV et al. Extended-release formulations of Tramadol in the treatment of chronic pain. Expert OpinPharmacother. 2011;8;12 (11): 1757-8. dol:10.1517/14656566.2011.57620. Epub 2011 May 24.
24. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;8:CD004959.
25. Schug SA. The role of Tramadol in current treatment strategies for musculoskeletal pain. Ther Clin Risk Manag. 2007;3(5):717-723.
26. Health Canada Drug Products Database [database on the Internet]. Ottawa: Health Canada. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. Accessed September 17, 2013.
27. Drugs @ FDA approved drug products [database on the Internet]. Silver Spring: Food and Drug Administration; 2006. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed September 17, 2013.
28. Raffa R. Pharmacological aspects of successful long-term analgesia. Clin Rheumatol. 2006;25 Suppl 1:S9-S15.
29. Bamigbade TA, Davidson C, Langford RM, Stamford JA. Actions of Tramadol, its enantiomers and principal metabolite, O-desmethylTramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth. 1997;79(3):352-356.
30. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets. Drugs. 2006;66(15):2017-2027; discussion 2028-2030.
31. Durela Canadian Product Monograph [webpage on the Internet]. Mississauga; Cipher Pharmaceuticals: 2012. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=85814&lang=eng. Accessed September 17, 2013.
32. Cipher Pharmaceuticals. ConZip Full Prescribing Information. Cipher Pharmaceuticals: 2012. Available from: http://www.verticalpharma.com/sites/vertical/files/ConZipPrescribingInfo.pdf. Accessed September 17, 2013.
33. Ultram® ER (Tramadol HCI) Extended-Release Tablets. Steinbech, MB: Valeant Pharmaceuticals International; 2012. Available from: http://www.janssenpharmaceuticalsinc.com/assets/ultramer.pdf. Accessed September 17, 2013.
34. Langley PC, Patkar AD, Boswell KA, Benson CJ, Schein JR. Adverse event profile of Tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin. Jan 2010;26(1):239-251.
35. Kah Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A; National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician. 2011;57(11):1257-1266, e407-e418.
36. Chou R, Fanciullo GJ, Fine PG, etal; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
37. Hochberg MC, Altman RD, April KT, etal; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
38. Coluzzi F, Mattia C. Chronic non-cancer pain: Focus on once-daily Tramadol formulations. Ther Clin Risk Manag. 2007;3(5):819-829.
39. Zytram XL Canadian Drug Product Monograph [webpage on the Internet]. Pickering, ON: Purdue Pharma; 2006. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=77188&lang=eng. Accessed September 17, 2013.
40. Valeant Canada LP/Valeant Canada SEC. Ralivia Canadian Drug Product Monograph [webpage on the Internet]. Pickering, ON: Purdue Pharma; 2006. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=77188&lang=eng. Accessed Month DD, YYYY.
41. Paladin Labs Inc. Tridural Canadian Drug Product Monograph [webpage on the Internet]. Saint-Laurent, QC: Paladin Labs Inc.; 2007. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=78172&lang=eng. Accessed September 17, 2013.
42. RYZOLT-Tramadol hydrochloride tablet, extended release [webpage on the Internet]. Stanford, CT: Purdue Pharma; 2011. Available from: http://app.purduepharma.com/xmlpublishing/pi.aspx?id=r. Accessed September 17, 2013.
43. Cipher Pharmaceuticals [homepage on the Internet]. Mississauga, ON; Cipher Pharmaceuticals: 2012. Available from: http://www.cipherpharma.com/. Accessed September 17, 2013.
44. Kizilbash A, Schwartz B, Mengle-Gaw L, Gross JA. Poster Abstracts 1. In Tramadol Formul Considerations Chronic Pain Manag Present 20th Annu Clin Meet l Integr Pain Manag Optim Patient Care. 52-80.
45. Woolf CJ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6): 441-451.
46. Beaulieu AD, Peloso P, Bensen W, etal. A randomized, double-blind, 8-week crossover study of once-daily controlled-release Tramadol versus immediate-release Tramadol taken as needed for chronic noncancer pain. Clin Ther. 2007;29(1):49-60.
47. McCarberg B. Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag. 2007;3(3):401-410.
48. Bodalia B, McDonald CJ, Smith KJ, O'Brien C, Cousens L. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily Tramadol tablets with normal release Tramadol capsules. J Pain Symptom Manage. 2003;25(2):142-149.
49. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral Tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994;5(2):141-146.
50. Højsted J, Sjøgren P. An update on the role of opioids in the management of chronic pain of nonmalignant origin. Curr Opin Anaesthesiol. 2007;20(5):451-455.
51. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily Tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28(1):59-71.
52. Dayer P, Desmeules J, Collart L. [Pharmacology of Tramadol]. Drugs. 1997;53 Suppl 2:18-24. French.
53. Fanoe S, Jensen GB, Sjøgren P, Korsgaard MP, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009;67(2):172-179.
54. Malonne H, Sonet B, Streel B, etal. Pharmacokinetic evaluation of a new oral sustained release dose form of Tramadol. Br J Clin Pharmacol. 2004;57(3):270-278.